The CDK4 and 6 inhibitor abemaciclib induces both epigenetic and immunogenic responses in preclinical models of Ewing's sarcoma

被引：0
|
作者：
Dowless, Michele [1 ]
Lowery, Caitlin [1 ]
Renschler, Matthew [1 ]
Blosser, Wayne [1 ]
Stephens, Jennifer [1 ]
Flack, Robert [1 ]
Credille, Kelly [1 ]
Chen, Mia [1 ]
Dorsey, Frank [1 ]
Sams, Lillian [1 ]
Ebert, Philip [1 ]
Olsen, Jonathan [1 ]
Shackleford, Terry [2 ]
Houghton, Peter [2 ]
Stancato, Louis [1 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] UT Hlth Sci Ctr, Greehey Childrens Canc Res Inst, San Antonio, TX USA
来源：
CANCER RESEARCH | 2018年 / 78卷 / 19期
关键词：
D O I：
10.1158/1538-7445.PEDCA17-B43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B43
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Preclinical evaluation of novel CDK4/6 inhibitor GLR2007 in breast and lung cancer models
    Yin, L.
    Yao, Z.
    Wang, Y.
    Huang, Y-H.
    Mazuranic, M.
    Yin, A.
    ANNALS OF ONCOLOGY, 2021, 32 : S362 - S362
  • [32] FDA approves Novartis's CDK4/6 inhibitor
    Mullard, Asher
    NATURE REVIEWS DRUG DISCOVERY, 2017, 16 (04) : 229 - 229
  • [33] Efficacy of CDK4/6 inhibitors in preclinical models of malignant pleural mesothelioma
    Aliagas, Elisabet
    Alay, Ania
    Martinez-Iniesta, Maria
    Hernandez-Madrigal, Miguel
    Cordero, David
    Gausachs, Mireia
    Pros, Eva
    Saigi, Maria
    Busacca, Sara
    Sharkley, Annabel J.
    Dawson, Alan
    Palmero, Ramon
    Ruffinelli, Jose C.
    Padrones, Susana
    Aso, Samantha
    Escobar, Ignacio
    Ramos, Ricard
    Llatjos, Roger
    Vidal, August
    Dorca, Eduard
    Varela, Mar
    Sanchez-Cespedes, Montse
    Fennell, Dean
    Munoz-Pinedo, Cristina
    Villanueva, Alberto
    Sole, Xavi
    Nadal, Ernest
    BRITISH JOURNAL OF CANCER, 2021, 125 (10) : 1365 - 1376
  • [34] CDK4 & 6 inhibitor Abemaciclib exerts intrinsic immunomodulatory effects on human T cells in vitro
    Chin, Darin
    Carpenito, Carmine
    Amaladas, Nelusha
    Chung, Linda
    Staschke, Kirk
    Schaer, David
    Beckmann, Richard
    Novosiadly, Ruslan
    Kalos, Michael
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [35] Molecular mechanism of vacuolar formation associated with cell death induced by CDK4/6 inhibitor abemaciclib
    Hino, Hirotsugu
    Tanaka, Yoshinori
    Okimoto, Tomoya
    Ikeda, Toshikatsu
    Hara, Tomoyo
    Takeya, Kosuke
    Takano, Naoharu
    Hiramoto, Masaka
    Aizawa, Shin
    Miyazawa, Keisuke
    Eto, Masumi
    Hirai, Shuichi
    CANCER SCIENCE, 2025, 116 : 1741 - 1741
  • [36] LY2835219, a selective inhibitor of CDK4 and CDK6, inhibits growth in preclinical models of human cancer.
    Dempsey, Jack A.
    Chan, Edward M.
    Burke, Teresa F.
    Beckmann, Richard P.
    CANCER RESEARCH, 2013, 73 (08)
  • [37] Synergistic effect of targeting both CDK4/6 and mTORin sarcoma cell lines
    Wang, Xiaochun
    Goldstein, David
    Crowe, Philip
    Yang, Jia-Lin
    CANCER RESEARCH, 2019, 79 (13)
  • [38] Targeting resistance mechanisms to CDK4/6 inhibitors in Ewing sarcoma with an IGF1R inhibitor drug combination strategy
    Guenther, Lillian M.
    Dharia, Neekesh V.
    Ross, Linda
    Conway, Amy S.
    Robichaud, Amanda L.
    Church, Alanna J.
    Guha, Rajarshi
    Davis, Mindy I.
    Alexe, Gabriela
    Mora, Jaume
    Piccioni, Federica
    Stegmaier, Kimberly
    CANCER RESEARCH, 2018, 78 (13)
  • [39] Mechanisms of abemaciclib, a CDK4/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro
    Eskiler, Gamze Guney
    Ozkan, Asuman Deveci
    Haciefendi, Ayten
    Bilir, Cemil
    TRANSLATIONAL ONCOLOGY, 2022, 15 (01):
  • [40] CDK4/6 inhibitor abemaciclib has been established in early as well as locally advanced and metastatic settings
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 (04) : 156 - 157
12345